Results 1 to 10 of about 256,130 (281)

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Improvement of Biophysical Properties and Affinity of a Human Anti-L1CAM Therapeutic Antibody through Antibody Engineering Based on Computational Methods. [PDF]

Int J Mol Sci, 2021
Chae H, Cho S, Jeong M, Kwon K, Choi D, Lee J, Nam W, Hong J, Lee J, Yoon S, Hong H.   +10 more
europepmc   +1 more source

Fc engineering for the reprogramming the effector functions of antibodies for improved therapeutic potency

, 2014
Tae Hyun Kang
openalex   +2 more sources

Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. [PDF]

, 2008
Xin Luo, Emily Maarschalk, Ryan M. O’Connell, Pin Wang, Lili Yang, David Baltimore   +5 more
openalex   +1 more source

Computational peptide engineering approach for selection of the new C05 antibody-driven peptide with potency to blocking influenza a virus attachment; from in silico to in vivo

, 2023
Shima Gholami, Ladan Mafakher, Fatemeh Fotouhi, Bijan Bambai, Reza Ahangari Cohan, Parvaneh Mehrbod, Hadiseh Shokouhi, Behrokh Farahmand   +7 more
openalex   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

ANABAG: AnnotatedAntibody–Antigen Data Setwith Unique Features for Antibody Engineering Applications [PDF]

Ilyas Grandguillaume (22450041), Fernando Luís Barroso da Silva (4439368), Catherine Etchebest (86630)   +2 more
openalex   +2 more sources

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Chimeric Antibody Engineering Against Bacillus anthracis Lethal Toxin: Neutralization Efficacy and Mechanism of Action. [PDF]

Toxins (Basel)
Kalmantaeva OV, Marin MA, Ershova AA, Ryabko AK, Romanenko YO, Kombarova TI, Dyatlov IA, Firstova VV.   +7 more
europepmc   +1 more source